Regeneron Pharmaceuticals announced that the FDA has approved Eylea (aflibercept) injection for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME), according to a company news release. In 2014, the FDA granted Eylea breakthrough therapy designation and priority review for the treatment of diabetic retinopathy in patients with DME. Diabetic retinopathy coupled […]

Leer Más "EYLEA RECEIVES FDA APPROVAL FOR THE TREATMENT OF DIABETIC RETINOPATHY IN PATIENTS WITH DME"